SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Wockhardt gets EIR with observations for 3 plants from USFDA

22 Jul 2016 Evaluate

The US health regulator has made observations in its Establishment Inspection Report (EIR) for Wockhardt’s three units in Maharashtra and ban on exports from the facilities to the US will continue. The company’s three facilities - Chikalthana and two units at Waluj in Maharashtra - have received EIR with observations. EIR is given to an establishment after the completion of the inspection by the US Food and Drug Administration (USFDA).

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.

Wockhardt Share Price

1393.00 -3.80 (-0.27%)
20-Apr-2026 09:21 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.60
Dr. Reddys Lab 1232.65
Cipla 1242.10
Zydus Lifesciences 944.25
Lupin 2328.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×